【摘要】 黄花夹竹桃甙（thevetoside,TS）属强心甙类药,1.5 mg·kg^-1·d^-1ip治疗小鼠腹水瘤H22,EAC,P388及实体瘤S180,U14,Lewis肺癌,仅对实体瘤有效,抑瘤率为48.7％—56.7％。TS与轻度抑瘤作用剂量(0.3,0.5或1.0 mg·kg^-1·d^-1)的氮芥合用,抑瘤活性高于单独给药组,能使腹水瘤小鼠的生存期延长率达到82.4至>122.1％;对实体瘤的抑瘤率为65.6％—72.5％更多还原

【Abstract】 Thevetoside (TS) is one of the cardiac glycosides. A study of antitumor activity was carried out in 6 types of murine tumors in vivo, such as the ascitic tumors H22, EAC, P388, and solid tumors S180, U14, Lewis lung carcinoma, which were treated with ip TS 1. 5 mg ·kg-1·d-1 alone or in combination with chlormethine (Ch1) 0. 3, 0. 5, or 1.0 mg·kg-1·d-1. TS only showed a remarkable inhibition on the growth of 3 types of solid tumors with inhibition rates of 48. 7% - 56. 7%. The effect of the combination therapy was much pronounced than that of independent administration. The life span under combined therapy was increased 82. 4% to >122. 1%. For solid tumors, the combinedadministration gave inhibition rates of 65. 6 %-72.5%.更多还原